MedTrace Logo

Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion

NCT00797550 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-05-11

No results posted yet for this study

Summary

The hypothesis is that Aastrom TRC autologous bone marrow tissue "grafts" can be safely used to promote bone healing as part of a single level posterolateral spine fusion surgical procedure.

Conditions

  • Single Level Posterolateral Spinal Fusion

Interventions

BIOLOGICAL

Bone Repair Cells (BRCs)

BRCs will be administered during spine fusion surgery

PROCEDURE

Autologous bone graft

Sponsors & Collaborators

  • Vericel Corporation

    lead INDUSTRY

Principal Investigators

  • Harry Herkowitz, MD · William Beaumont Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2006-08-31
Completion
2008-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00797550 on ClinicalTrials.gov